Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
September 09 2022 - 8:30AM
Business Wire
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the
Company), a late clinical-stage biopharmaceutical company aiming to
transform the treatment landscape for individuals living with
anxiety, depression and other central nervous system (CNS)
disorders, today announced that Chief Executive Officer, Shawn
Singh, will participate in the following upcoming investor
conferences in New York. Management will be available for
one-on-one meetings during these conferences.
Morgan Stanley 20th Annual Global Healthcare
Conference
Format: Fireside Chat Date and Time: Tuesday, September 13th at
9:10 a.m. Eastern Time Location: New York, New York Webcast will be
accessible through the Events page in the Investors section of the
Company’s website at www.Vistagen.com.
Baird 2022 Global Healthcare Conference
Format: Fireside Chat Date and Time: Wednesday, September 14th
at 2:35 p.m. Eastern Time Location: New York, New York
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused
biopharmaceutical company striving to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available.
Vistagen’s clinical-stage candidates are targeting multiple forms
of anxiety and depression. PH94B and PH10 belong to a new class of
drugs known as pherines, which are odorless and tasteless
investigational neuroactive steroids designed with a novel
rapid-onset mechanism of action that activates chemosensory neurons
in the nasal passages and can impact the olfactory-amygdala neural
circuits without systemic uptake or direct activity on CNS neurons
in the brain. Vistagen is passionate about transforming mental
health care and redefining what is possible in the treatment of
anxiety and depression. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220909005140/en/
Investors: Mark Flather Vice President, Investor
Relations (650) 577-3617 mflather@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024